dr-michelle-hermiston-md-104-1440x784-2x
dr-michelle-hermiston-md-104-320x320-2x

Michelle L. Hermiston

MD PhD

Pediatric hematologist and oncologist

Dr. Michelle L. Hermiston is a specialist in caring for children with blood diseases, including cancers of the blood. In research, she has a special interest in defining the underlying mechanisms in the development of lymphoid malignancies, including leukemia and lymphoma.

Hermiston earned her medical degree and a doctorate in developmental biology at Washington State University. She completed a residency in pediatrics and a fellowship in pediatric hematology and oncology at UCSF before joining the faculty in 2002. She also participated in a medical scientist training program at Washington University and in the UCSF Molecular Medicine Research Fellowship Program.

Hermiston is a member of numerous professional organizations, including the American Society of Hematology and American Academy of Pediatrics.

  • Education

    Washington University , MD, 1997

  • Residencies

    UCSF, Pediatrics, 1999

  • Fellowships

    UCS, Pediatric Hematology and Oncology, 2002

Related conditions

Clinics I work with

(3)

blood-and-marrow-transplant-clinic-320x320-2x 3

Blood & Marrow Transplant (BMT) Clinic

Blood & Marrow Transplant (BMT) Clinic

San Francisco / Oakland
hematology-clinic-320x320-2x 5

Hematology Clinic

Hematology Clinic

San Francisco / Oakland / Santa Rosa / Walnut Creek
oncology-clinic-320x320-2x 3

Oncology Clinic

Oncology Clinic

San Francisco / Oakland / Walnut Creek

Where I see patients (3)

Expand Map

    Selected research

    Decorative Caduceus

    Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemo...

    The incidence of dose limiting toxicity (DLT) will be measured at different dose levels.

    Recruiting

    More about this study
    Decorative Caduceus

    Epigenetic Reprogramming in Relapse/Refractory AML

    The incidence of dose limiting toxicity (DLT) will be measured. The maximum tolerated dose will be the highest study dose at which 1 or fewer of six patients experience DLT during cycle 1 of therapy

    Recruiting

    More about this study
    See all clinical trials

    Contact me

    Saving future lives

    500+ UCSF investigators are researching cures for hundreds of childhood and adult diseases.

    Share